A Study to Examine Atropine for the Reduction of Nearsightedness (The CHAPERONE Study)

Official Title

Microdosed Atropine for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)


The purpose of this study to test the safety and effectiveness of atropine 0.1% and atropine 0.01% eye solutions. These drugs are being tested to see if they slow the worsening of nearsightedness. Children who participate in this study will be asked to use their assigned study medication every night and willing to attend visits at The Ohio State University of Optometry 1 month after starting treatment. These visits will continue for 6 months until the duration of the study ends. This study will take place over a 4-year time period.

Could this study be right for you?

· Children aged 3 to < 13 years old. · No previous use of medications related to myopia control. · Glasses and/or contact lens prescription between -1.00 and -6.00 diopters. Interested guardians who believe their child may be eligible should contact study coordinators to further determine eligibility

Age Range

3 and up